Literature DB >> 947956

The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.

S D Revak, C G Cochrane.   

Abstract

Three regions of the human Hageman factor molecule termed the c, d, and e regions have been defined. Division of the molecule into these three regions is based on the analysis of fragments obtained by enzymatic cleavage during fluid-phase activation. The three regions have the following properties: (a) the c region has a mol wt of 40,000, has the capacity to bind to negatively charged surfaces, and does not have detectable enzymatic activity; (b) the e region possess a mol wt of 28,000 has enzymatic activity, and does not bind to negatively charged surfaces; (c) the d region has a mol wt of 12,000, is located between the c and e fragments but has not been detected as a freely existing polypeptide, and can bind firmly to negatively charged surfaces. The preparation of antibodies specific for the c and e regions is described as well as their use in defining the electrophoretic characteristics of the cde, cd, de, c, and e polypeptide fragments of Hageman factor. Evidence is given showing that the e region, but not the c or d, is released from a negatively charged surface when bound Hageman factor is exposed to proteolytic enzymes or whole plasma and that when this occurs in the presence of normal plasma, the e fragment becomes bound to C1 esterase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947956      PMCID: PMC436728          DOI: 10.1172/JCI108361

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation.

Authors:  J MARGOLIS
Journal:  J Physiol       Date:  1958-11-10       Impact factor: 5.182

2.  [A micro-method of immuno-electrophoresis].

Authors:  J J SCHEIDEGGER
Journal:  Int Arch Allergy Appl Immunol       Date:  1955

3.  [Method permitting the combined study of the electrophoretic and the immunochemical properties of protein mixtures; application to blood serum].

Authors:  P GRABAR; C A WILLIAMS
Journal:  Biochim Biophys Acta       Date:  1953-01

4.  Activated human Hageman factor (XII).

Authors:  R J Speer; H Ridgway; J M Hill
Journal:  Thromb Diath Haemorrh       Date:  1965-09-01

5.  Structural changes accompanying enzymatic activation of human Hageman factor.

Authors:  S D Revak; C G Cochrane; A R Johnston; T E Hugli
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

Review 6.  Human plasma kallikrein, its activation and pathological role.

Authors:  M E Webster
Journal:  Fed Proc       Date:  1968 Jan-Feb

7.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

8.  Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.

Authors:  C G Cochrane; S D Revak; K D Wuepper
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

9.  Plasma prekallikrein: isolation, characterization, and mechanism of activation.

Authors:  K D Wuepper; C G Cochrane
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

10.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Kallikreins and kinins: mediators in inflammatory joint disease?

Authors:  K Worthy; C D Figueroa; P A Dieppe; K D Bhoola
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

Review 2.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

3.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

4.  Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors.

Authors:  Alexey Dementiev; Abel Silva; Calvin Yee; Zhe Li; Michael T Flavin; Hing Sham; James R Partridge
Journal:  Blood Adv       Date:  2018-03-13

5.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

Authors:  B Ghebrehiwet; B P Randazzo; J T Dunn; M Silverberg; A P Kaplan
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

6.  Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.

Authors:  J E Sealey; S A Atlas; J H Laragh; M Silverberg; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

7.  Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q.

Authors:  E H Rehmus; B M Greene; B A Everson; O D Ratnoff
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

Review 8.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

9.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

10.  Guinea pig Hageman factor as a vascular permeability enhancement factor.

Authors:  T Yamamoto; C G Cochrane
Journal:  Am J Pathol       Date:  1981-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.